HIV-1 integrase (IN) is a primary target for combination antiretroviral therapy. Only a limited number of studies report on the emergence of resistance-associated mutations (RAMs) in Cameroon. We observed that 1.4% of sequence from treatment-naive patients had IN strand transfer inhibitor (INSTI) RAMs. These mutations confer resistance to raltegravir and elvitegravir. We also observed that 10.1% of the sequences have INSTI accessory RAMs. HIV-1 CRF02_AG was the predominant subtype (44.7%) in this study analyses. The occurrence of INSTI RAMs among the sequences at baseline needs to be monitored carefully.

中文翻译：

---

喀麦隆来源的整合酶序列的 HIV-1 耐药突变分析。

HIV-1 整合酶 (IN) 是联合抗逆转录病毒治疗的主要目标。只有少数研究报告了喀麦隆出现耐药相关突变 (RAM)。我们观察到 1.4% 的未治疗患者序列具有 IN 链转移抑制剂 (INSTI) RAM。这些突变赋予对 raltegravir 和 elvitegravir 的耐药性。我们还观察到 10.1% 的序列具有 INSTI 附件 RAM。HIV-1 CRF02_AG 是本研究分析中的主要亚型 (44.7%)。需要仔细监测基线序列中 INSTI RAM 的出现。